STEP : Eligibility at time of generating and infusing CMV-specific cytotoxic T cells (adoptive immunotherapy): documented CMV end-organ disease
Evidence of end-organ Cytomegalovirus (CMV) infection
CMV PCR >  copies/mL or evidence of end-organ damage due to CMV
History of CMV end-organ disease within  months before randomization
